By Mary Van Doren, from the Volume XXVI No. 7 – May 20, 2019 issue
This is an excerpt from a 3,380-word article in the May 20, 2019 issue of THE DARK REPORT. The full article is available to members of The Dark Intelligence Group.
CEO SUMMARY: To develop new sources of revenue to offset declining fee-for-service payments, TriCore Reference Labs is collaborating with health insurers in novel ways to improve patient
By Joseph Burns, from the Volume XXVI No. 7 – May 20, 2019 issue
CEO SUMMARY: To develop new sources of revenue to offset declining fee-for-service payments, TriCore Reference Labs is collaborating with health insurers in novel ways to improve patient outcomes and lower healthcare costs. To achieve this, TriCore brings together data from lab tests, EHRs, patient demographics, and geography. Analytical tools allow it to assess population health
By Joseph Burns, from the Volume XXV No. 16 – November 13, 2018 issue
CEO SUMMARY: No bigger threat looms over the financial security of the nation’s clinical laboratories than healthcare’s transition from fee-for-service payment to value-based reimbursement. To navigate that transition successfully, medical labs and pathology groups will need to adopt the Clinical Lab 2.0 model. Member labs of Project Santa Fe are themselves working to develop and
By Robert Michel, from the Volume XXV No. 15 – October 22, 2018 issue
Efforts to enroll one million veterans in a program to determine how genetic variations affect health is moving swiftly. Current enrollment is 700,000 veterans and the one million goal is expected to be reached by 2021. In 2011, the federal Department of Veterans Affairs instituted the VA Million Veterans Program (MVP).
MORE ON: Million Vets
Recently the VA extended
By Robert Michel, from the Volume XXV No. 5 – March 26, 2018 issue
On March 6, one of the lab industry’s long-serving executives and consultants, Jack Mattice, PhD, of Vancouver, Wash., died from flu complications. He was 77 years old. Mattice earned a PhD in medical microbiology from University of Oregon. Within a few years, he was handling market development for United Medical Laboratories (UML), of Portland, Ore. UML reached
By Robert Michel, from the Volume XXV, No. 1 – January 2, 2018 issue
In Arizona, individuals and patients who paid for clinical laboratory tests performed by Theranos, Inc., are finally getting refunds. These payments are a result of a settlement between the Arizona Attorney General and Theranos. News accounts indicate that, over the time in 2013 through 2016 that Theranos offered lab tests in Arizona through its relationship with
By Mary Van Doren, from the Volume XXIV, No. 7 – May 15, 2017 issue
This is an excerpt from an 850-word article in the May 15, 2017, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group.
CEO SUMMARY: There are few places and times where a broad cross-section of
By Robert Michel, from the Volume XXIV, No. 12 – August 28, 2017 issue
Genetic testing for dogs is the goal of Embark Veterinary, of Boston, Mass. Founded in 2015, the company just raised $4.5 million from investors, including Anne Wojcicki, founder of 23andMe. Company executives say the genetic testing will help vets, pet owners, and breeders identify the disease risk of the dogs, as well as the animals’
By Robert Michel, from the Volume XXIV, No. 9 – June 26, 2017 issue
CEO SUMMARY: News that Quest Diagnostics had exited the long-running CompuNet Clinical Laboratory joint venture in Dayton, Ohio, caught many observers by surprise. The only clues as to possible problems and the motivation of Premier Health, the 51% owner, to buy out Quest’s ownership share are contained in an announcement the health system issued. The
By Joseph Burns, from the Volume XXIV, No. 8 – June 5, 2017 issue
CEO SUMMARY: By now, there is widespread recognition among pathologists and clinical lab managers that the era of fee-for-service reimbursement is giving way to new forms of payment that reward value. First-mover lab leaders are in the earliest stages of developing enhanced lab testing services that contribute to improved patient outcomes while reducing costs. These
